125I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal Carcinoma

Lei Li,Jie Yang,Xiaojiang Li,Xiaoli Wang,Yanxin Ren,Jimin Fei,Yan Xi,Ruimei Sun,Jing Ma 대한이비인후과학회 2016 Clinical and Experimental Otorhinolaryngology Vol.9 No.3

Objectives. The aim of this study was to investigate the feasibility and safety of percutaneous 125I seed permanent implantation for advanced hypopharyngeal carcinoma from toxicity, tumor response, and short-term outcome. Methods. 125I seeds implant procedures were performed under computed tomography for 34 patients with advanced hypopharyngeal carcinoma. We observed the local control rate, overall survival, and acute or late toxicity rate. Results. In the 34 patients (stage III, n=6; stage IV, n=28), the sites of origin were pyriform sinus (n=29) and postcricoid area (n=5). All patients also received one to four cycles of chemotherapy after seed implantation. The post-plan showed that the actuarial D90 of 125I seeds ranged from 90 to 158 Gy (median, 127 Gy). The mean follow-up was 12.3 months (range, 3.4 to 43.2 months). The local control was 2.1–31.0 months with a median of 17.7 months (95% confidence interval [CI], 13.4 to 22.0 months). The 1-, 2-, and 3-year local controls were 65.3%, 28.6%, and 9.5% respectively. Twelve patients (35%) died of local recurrence, fourteen patients (41%) died of distant metastases, and three patients (9%) died of recurrence and metastases at the same time. Five patients (15%) still survived to follow-up. At the time of analysis, the median survival time was 12.5 months (95% CI, 9.5 to 15.4 months). The 1-, 2-, and 3-year overall survival rates were 55.2%, 20.3%, and 10.9%, respectively. Five patients (15%) experienced grade 3 toxic events and nine patients (26%) have experienced grade 2 toxic events. Conclusion. This review shows relatively low toxicity for interstitial 125I seed implantation in the patients with advanced stage hypopharyngeal cancer. The high local control results suggest that 125I seed brachytherapy implant as a salvage or palliative treatment for advanced hypopharyngeal carcinoma merit further investigation.

Synthesis of Phosphorous Phenanthrene/L-Tryptophan Flame Retardant for Enhanced Flame Retardancy of Epoxy Resins

Li Li,Fenglin Hua,Hui Xi,Jing Yang,Ting Xiao,Rui Zuo,Xueqing Xu,Zhiwang Yang,Ziqiang Lei 한국고분자학회 2022 Macromolecular Research Vol.30 No.12

A new type of phosphorus-containing intrinsic flame retardant was prepared with L-tryptophan (L-Trp) and 9,10-dihydro-9-oxa-10-phosphorbenzophenanthrene- 10-oxide (DOPO) as the main components. The Schiff base from the reaction of 1,4-terephthalaldehyde and L-tryptophan provides active sites, and then the phosphorous compound, DOPO, is successfully introduced into the Schiff base to synthesize L-Trp-DOPO flame retardant. The intrinsic flame retardant property of LTrp- DOPO comes from the reaction of carbonyl groups and the epoxy groups in epoxy resin (EP) matrix. The prepared L-Trp-DOPO flame retardant can efficiently improve the flame retardancy and smoke suppression of the base material of EP. Cone calorimetric test (CCT) of EP/L-Trp-DOPO composite material was carried out. The data showed that the peak heat release rate (pk-HRR) value was reduced by 50.8% (from 1459 kW/m2 to 717 kW/m2), the THR value reduced by 78.3%, and the limiting oxygen index (LOI) value was increased by 24%. The addition of new flame retardant greatly reduced the release of toxic CO gas. The flame retardant mechanism was explored, and it can be found that after thermal decomposition of L-Trp- DOPO a dense carbon layer can be produced to isolate the fire source. In addition, during the combustion process, L-Trp-DOPO will produce phosphorus-containing free radicals which will quench the active free radicals in the gas phase and dilute the combustible gas. The prepared L-Trp-DOPO flame retardant has a flame retardant effect in both the condensed phase and the gas phase during the combustion process.

Flame Retardancy of Epoxy Resin Improved by Graphene Hybrid Containing Phosphorous, Boron, Nitrogen and Silicon Elements

Li Li,Huan Wang,Fenglin Hua,Mingming Wang,Yuanshuo Zhang,Hui Xi,Jing Yang,Zhiwang Yang,Ziqiang Lei 한국고분자학회 2021 Macromolecular Research Vol.29 No.9

An effective ternary organic-inorganic composite flame retardant of reduced graphene oxide-poly-dopamine@graphitic carbon nitride@10-(2,5-dihydroxyphenyl)- 10-H-9-oxa-10-phosphaphenanthrene-10-oxide (RGO-PDA@g-C3N4@ODOPB) was successfully fabricated by co-precipitation method. Its property concerning the intrinsic flame retardancy and the mechanical performance was well studied when it was used as co-additives in combination with ammonium polyphosphate (APP) in epoxy resin (EP) samples. The surface morphology and the structure of RGO-PDA@g-C3N4 @ODOPB were characterized by SEM, and the molecular structure and compositions were investigated by FT-IR, powder XRD and 1H NMR. TGA, limit oxygen index (LOI), vertical burning test (UL-94), cone calorimeter test, and SEM were also used to investigate the thermal properties and flame retardancy of materials. As expected, the flame retardancy of EP was significantly heightened after adding of RGOPDA@ g-C3N4@ODOPB composites. It showed that with the 20% adding of RGO-PDA@g-C3N4@ODOPB/APP into EP led to the decreasing of the peak heat release rate and the total heat release at 78% and 62.5%, respectively. Meanwhile, the LOI value of the EP composites was as high as 29% and reached UL-94 V-0 rate. It was deemed that the excellent flame retardancy was attributed to the forming of compact and stable carbon layer, which was being catalytic carbonization by APP existed in the RGO-PDA@g-C3N4@ODOPB/APP composites. At the same time, the non-combustible gas released from thermal cracking of g-C3N4 during the combustion also benefited the flame retardant performance of EP.

Four-Hour Fasting for Semifluids and 2-Hour Fasting for Water Improves the Patient Experience of Esophagogastroduodenoscopy: A Randomized Controlled Trial

Cai Meng-Xi,Gao Ye,Li Li,Feng Wen,Wang Yi-Lin,Li Zhao-Shen,Xin Lei,Wang Luo-Wei 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.3

Background/Aims: We aimed to investigate the comfort, safety, and endoscopic visibility during esophagogastroduodenoscopy (EGD) afforded by a modified 4-hour semifluid and 2-hour water (“4+2”) fasting protocol. Methods: In this parallel group, endoscopist-blinded, randomized controlled trial, outpatients undergoing unsedated diagnostic EGD from 10:30 AM to 12:00 PM were randomly assigned to either a “4+2” protocol group or a conventional fasting group. The participants’ comfort during the fasting period and procedure was measured using the visual analog scale, and mucosal visibility was measured by endoscopists using the total visibility score. Satisfaction was defined as a visual analog scale score of ≤3. The primary outcome was the participants’ comfort during fasting. Results: One hundred and six and 108 participants were randomized to the “4+2” protocol and control groups, respectively. Participants’ comfort before EGD was significantly higher in the “4+2” protocol group measured by both the proportion of satisfaction (86.8% vs 63.9%, p=0.002) and the visual analog scale score (median [interquartile range]: 1.0 [1.0–2.0] vs 3.0 [1.0–4.0], p<0.001). The proportion of satisfaction during EGD also significantly improved (59.4% vs 45.4%, p=0.039) in the “4+2” protocol group. The total visibility score was unaffected by the fasting protocol (5.0 [4.0–5.0] vs 4.0 [4.0–5.0], p=0.266). No adverse events were observed during the study. Conclusions: The “4+2” protocol was more comfortable and provided equal mucosal visibility and safety compared with conventional fasting for unsedated EGD. (

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis

Ying Yang,Dong Wang,Lei Cui,Hong-Hao Ma,Li Zhang,Hong-Yun Lian,Qing Zhang,Xiao-Xi Zhao,Li-Ping Zhang,Yun-Ze Zhao,Na Li,Tian-You Wang,Zhi-Gang Li,Rui Zhang 대한암학회 2021 Cancer Research and Treatment Vol.53 No.1

Purpose We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH). Materials and Methods A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib. Results The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO– group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients. Conclusion Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.

Robust Visual Inertial Odometry Estimation Based on Adaptive Interactive Multiple Model Algorithm

Lei Wang,Shicheng Xia,Hengliu Xi,Shuangxi Li,Le Wang 제어·로봇·시스템학회 2022 International Journal of Control, Automation, and Vol.20 No.10

In this paper, we focus on the problem of motion tracking in unknown environments using visual and inertial sensors, commonly known as visual-Inertial odometer (VIO) tasks. Currently, there are two main types of estimation methods to achieve VIO estimation, the filter-based method and the optimization-based method. We combine multi-state-constraint Kalman filter (MSCKF) algorithm with interactive multi-model algorithm and propose a novel filter-based VIO method. Compared with the VIO algorithm based on extended Kalman filter (EKF), the MSCKF algorithm has less strict probability assumption and better accuracy and consistency. However, traditional EKF and MSCKF algorithms both adopt a single fixed system model, which is difficult to adapt to complex and changeable application scenarios. To solve this problem, we introduce the adaptive multi-model method into the MSCKF algorithm, and combine the two to build an interactive multi-model MSCKF (IMM-MSCKF) algorithm. In the proposed IMM-MSCKF algorithm, several model sub-filters are designed, and their results are fused by transition probability to obtain the optimal state estimation. The common data set KITTI is used to verify the proposed IMM-MSCKF algorithm. Experiment results show that the proposed novel algorithm has better estimation accuracy and robustness compared with other solutions based on multi-state constraint Kalman filter. The IMM-MSCKF algorithm can achieve long-term, high-precision and consistent real-time VIO tasks.

Kinetic modeling of C2–C7 olefins interconversion over ZSM-5 catalyst

Lei Ying,Jiajia Zhu,Youwei Cheng,Lijun Wang,Xi Li 한국공업화학회 2016 Journal of Industrial and Engineering Chemistry Vol.33 No.-

The kinetics of C2–C7 olefins interconversion were studied by feeding individual olefin into industrialZSM-5 catalyst at temperatures of 400–490 8C, space time of 0.0046–0.34 h and partial pressure of13.1 kPa. A kinetic model involving oligomerization, cracking and aromatization of olefins wasestablished. The results showed that the calculated apparent activation energy was negative foroligomerization reactions and positive for cracking reactions. The proposed kinetic model was able topredict the product concentrations in the C2–C7 olefins interconversion over ZSM-5 catalyst, with R2values ranged from 0.969 to 0.996 for the major species.

Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer

Li-jun Liang,Chen-xi Hu,Yi-xuan Wen,Xiao-wei Geng,Ting Chen,Guo-qing Gu,Lei Wang,You-you Xia,Yong Liu,Jia-yan Fei,Jie Dong,Feng-hua Zhao,Yiliyar Ahongjiang,Kai-yuan Hui,Xiao-dong Jiang 대한암학회 2020 Cancer Research and Treatment Vol.52 No.2

Purpose This study aimed to investigate the potential systemic antitumor effects of stereotactic ablative radiotherapy (SABR) and apatinib (a novel vascular endothelial growth factor receptor 2 inhibitor) via reversing the immunosuppressive tumor microenvironment for lung carcinoma. Materials and Methods Lewis lung cancer cells were injected into C57BL/6 mice in the left hindlimb (primary tumor; irradiated) and in the right flank (secondary tumor; nonirradiated). When both tumors grew to the touchable size, mice were randomly divided into eight treatment groups. These groups received normal saline or three distinct doses of apatinib (50 mg/kg, 150 mg/kg, and 200 mg/kg) daily for 7 days, in combination with a single dose of 15 Gy radiotherapy or not to the primary tumor. The further tumor growth/regression of mice were followed and observed. Results For the single 15 Gy modality, tumor growth delay could only be observed at the primary tumor. When combining SABR and apatinib 200 mg/kg, significant retardation of both primary and secondary tumor growth could be observed, indicated an abscopal effect was induced. Mechanism analysis suggested that programmed death-ligand 1 expression increased with SABR was counteract by additional apatinib therapy. Furthermore, when apatinib was combined with SABR, the composition of immune cells could be changed. More importantly, this two-pronged approach evoked tumor antigen–specific immune responses and the mice were resistant to another tumor rechallenge, finally, long-term survival was improved. Conclusion Our results suggested that the tumor microenvironment could be managed with apatinib, which was effective in eliciting an abscopal effect induced by SABR.

MTHFR Polymorphisms and Pancreatic Cancer Risk:Lack of Evidence from a Meta-analysis

Li, Lei,Wu, Sheng-Di,Wang, Ji-Yao,Shen, Xi-Zhong,Jiang, Wei Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.5

Objective: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms have been reported to be associated with pancreatic cancer, but the published studies had yielded inconsistent results.We therefore performed the present meta-analysis. Methods: A search of Google scholar, PubMed, Cochrane Library and CNKI databases before April 2012 was conducted to summarize associations of MTHFR polymorphisms with pancreatic cancer risk. Assessment was with odds ratios (ORs) and 95% confidence intervals (CIs). Publication bias were also calculated. Results: Four relative studies on MTHFR gene polymorphisms (C667T and A1298C) were involved in this meta-analysis. Overall, C667T(TT vs. CC : OR = 1.61, 95%CI = 0.78 - 3.34; TT vs. CT : OR = 1.41, 95%CI = 0.88-2.25; dominant model: OR = 0.68, 95%CI = 0.40-1.17; recessive model: OR = 0.82, 95%CI = 0.52-1.30) and A1298C(CC vs. AA:OR=1.01, 95%CI=0.47-2.17; CC vs. AC: OR=0.99,95%CI=0.46-2.14; dominant model: OR=1.01, 95%CI = 0.47-2.20; recessive model: OR = 1.01, 95%CI = 0.80-1.26) did not increase pancreatic cancer risk. Conclusion: This meta-analysis indicated that MTHFR polymorphisms (C667T and A1298C) were not associated with pancreatic cancer risk.

The pregnancy outcomes of day-5 poor-quality and day-6 high-quality blastocysts in single blastocyst transfer cycles

Guang-li Zhang,Tian-yi Sun,Sen Li,Man-xi Jiang,Lei Guo The Korean Society for Reproductive Medicine 2023 Clinical and Experimental Reproductive Medicine Vol.50 No.1

Objective: This study compared the outcomes of single blastocyst transfer cycles, using day- 5 poor-quality blastocysts and day-6 high-quality blastocysts. Methods: We analyzed 462 frozen-thawed embryo transfer (FET) cycles performed at our center from January 2014 to December 2019. The cycles were divided into two groups: a day-5 poor-quality blastocyst transfer group (group A) and a day-6 high-quality blastocyst transfer group (group B). The clinical outcomes were tested. Results: In groups A and B, respectively, the clinical pregnancy rate (CPR; 61.65% vs. 67.17%, p=0.258), implantation rate (IR; 61.65% vs. 67.17%, p=0.258), and live birth rate (LBR; 69.51% vs. 77.83%, p=0.134) showed no significant differences. Moreover, when day-3 embryo quality was considered, the CPR, IR, and LBR were also similar in group A and group B (p>0.05). Conclusion: The clinical outcomes of day-5 poor-quality blastocysts and day-6 high-quality blastocysts were similar, suggesting that the developmental speed of the embryo might be more important than embryo quality for the clinical outcomes of single blastocyst transfer in FET cycles.